Lyxumia® (lixisenatid) får europeiskt godkännande för behandling av typ 2-diabetes
Sanofi lanserar ny behandling: den första prandiella GLP-1 receptoragonisten, som tas en gång per dag i samband med måltid
-
-
Sanofi President, Global Operations, to retire
Sanofi (EURONEXT : SAN and NYSE : SNY) announced today that Hanspeter Spek, President, Global Operations, will retire from his current role in mid-2013. A succession plan will be announced in due course.
-
Sanofi Compounds to be Featured in 178 Abstracts at American Society of Hematology Annual Meeting
Sanofi announced today that new research spanning the company’s marketed and investigational hematology products, including its late-stage selective JAK2 inhibitor, will be featured in 178 abstracts to be presented at the 2012 Annual Meeting of the American Society of Hematology in Atlanta, GA., December 8-11, 2012.
-
Sanofi Ranks Third on the Access to Medicine Foundation’s 2012 ATM Index
Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it ranked third among twenty pharmaceutical companies on the 2012 Access to Medicine Index (ATM Index) created by the Access to Medicine Foundation, an international non-profit organization dedicated to improving access to medicine to societies in need.
-
Sanofi får positivt utlåtande från CHMP för Lyxumia® (lixisenatid) för behandling av vuxna med typ 2-diabetes
Sanofi meddelade idag att kommittén för humanläkemedel (CHMP) vid Europeiska läkemedelsmyndigheten (EMA) har utfärdat ett positivt yttrande där man rekommenderar godkännande av Lyxumia ® (lixisenatid) en gång dagligen för behandling av vuxna med typ 2-diabetes för att uppnå glykemisk kontroll i kombination med orala glukossänkande läkemedel och/eller basinsulin.
-
Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes
Sanofi and T1D Exchange, a non-profit organization focused on type 1 diabetes, announced today on World Diabetes Day that they will collaborate on the TEENs registry study. The aim of the study is to provide the type 1 diabetes community with a better understanding of how children, adolescents and young adults are currently living with type 1 diabetes.
-
Att leva med förmaksflimmer
Hjärt- och Lungsjukas Riksförbund har tillsammans med Sanofi producerat Flimmerrapporten som presenteras idag. Omkring 210 000 svenskar beräknas lida av förmaksflimmer. Risken att få sjukdomen ökar med åldern och var fjärde person över 40 år förväntas drabbas av förmaksflimmer någon gång i livet.
-
Genzyme Announces Publication of LEMTRADA (alemtuzumab) Pivotal Studies in The Lancet
Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today the publication of results from the LEMTRADA™ (alemtuzumab) CARE-MS I and CARE-MS II pivotal studies in patients with relapsing-remitting multiple sclerosis (MS) in the November 1, 2012, online issue of The Lancet.
-
Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that results from a Phase 2 trial of SAR236553/REGN727 in patients with primary hypercholesterolemia were published in the October 31, 2012 issue of the New England Journal of Medicine.
-
Genzyme Presents Second Phase III Study of Once-daily Oral AUBAGIO® (teriflunomide) Confirming Significant Impact on Disability
Sanofi and its subsidiary Genzyme announced today that key data from the TOWER trial were presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
-
Genzyme to Present New Data from AUBAGIO® and LEMTRADATM Clinical Development Programs at ECTRIMS
Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today new data from Genzyme’s clinical development programs for AUBAGIO® (teriflunomide) and LEMTRADA TM (alemtuzumab) will be presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France, October 10-13.
-
Journal of Clinical Oncology Publishes Phase III Results of ZALTRAP® (aflibercept) VELOUR Study in Previously Treated Metastatic Colorectal Cancer
Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that detailed results from the pivotal Phase III VELOUR study evaluating ZALTRAP® (aflibercept) Injection for Intravenous Infusion for the treatment of patients with previously treated metastatic colorectal cancer were published in the October 2012 edition of the Journal of Clinical Oncology (JCO).
Visa mer
Loading...